Drug Profile
Ponezumab
Alternative Names: Anti-human Aβ28-40 IgG1; Antibody 2286; PF-04360365; PF-4,360,365; RN 1219Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Rinat Neuroscience
- Developer Pfizer
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Cerebral amyloid angiopathy
Most Recent Events
- 04 May 2016 Discontinued - Phase-II for Cerebral amyloid angiopathy in USA, United Kingdom, Canada, France, Netherlands (IV) (Pfizer pipeline, May 2016)
- 01 Sep 2015 Pfizer completes a phase II trial in Cerebral amyloid angiopathy in USA, Canada, France, Netherlands and United Kingdom (IV) (NCT01821118)
- 07 Nov 2014 Phase-II clinical trials in Cerebral amyloid angiopathy in France (IV)